Results 171 to 180 of about 1,424,424 (268)

Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA). [PDF]

Oncologist
Sherry AD, Meimoun N, Miller AM, Liu J, Chauhan K, Kouzy R, Lin TA, Msaouel P, Ludmir EB.   +8 more
europepmc   +1 more source

Spatial and Volumetric Characteristics of Glioblastoma: Associations With Clinical Presentation and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We aim to comprehensively analyze how regional tumor and edema characteristics are associated with clinical presentations and survival outcomes in a large cohort of glioblastoma patients. Methods Patients with IDH‐wildtype glioblastoma who received brain MRI from 2010 to 2023 were included.
Daniel J. Zhou, Marc Jaskir, Julian Gal, Yombe Fonkeu, Christos Davatzikos, MacLean P. Nasrallah, Jose Garcia, Rubo Xing, Stephen J. Bagley, Arati Desai, Richard E. Phillips, Steven Tobochnik, Colin A. Ellis, James J. Gugger, Nishant Sinha, Joel M. Stein, Kathryn A. Davis   +16 more
wiley   +1 more source

Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy. [PDF]

Cancers (Basel)
Bartalini L, Rimini M, Ikeda M, Abidoye O, Lucchetti J, Antonuzzo L, Kim JW, Vogel A, Lamarca A, Nichetti F, Saborowski A, Pressiani T, Vivaldi C, Rapposelli IG, Dekervel J, Braconi C, Pinato DJ, Tamburini E, Pircher CC, Tamberi S, Castet F, Verrico M, Parisi A, Couto N, Chon HJ, Martirena A, Landriscina M, Finkelmeier F, Oneda E, Avallone A, Dell'Aquila E, Perkhofer L, Kim IH, Formica V, de Sousa Pinto CM, Garajova I, Kang B, Corallo S, Fenocchio E, Farinea G, Pastorino A, Diana A, Yoo C, Schirripa M, Rodriquenz MG, Scartozzi M, Zumstein L, Ghidini M, Prager GW, Aprile G, Spinelli GP, Su YY, Chan SL, Warmington E, Lancianese A, Satake T, Bekaii-Saab T, Lavacchi D, Passeri L, Ferrara M, Kang M, Prete AA, Bozzarelli S, Persano M, Pretta A, Masi G, Balsano R, Niger M, Lonardi S, Salani F, Camera S, Fornaro L, Casadei-Gardini A, Rimassa L.   +73 more
europepmc   +1 more source

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro, Shiwen Koay, Gordon T. Ingle, Patricia McNamara, Laura Watson, Fion Bremner, Valeria Iodice   +6 more
wiley   +1 more source

Orphans of oncology

Journal of Cancer Research and Therapeutics, 2014
openaire   +2 more sources

Blood RNA Biomarker Signatures for Early Diagnosis and Prognosis in Ischemic and Hemorrhagic Stroke: The IBIS‐CT1 Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the expression of nine blood RNA biomarkers in a clinical trial based on genes previously identified in an experimental monkey model of stroke for diagnosis feasibility and prognostication. Methods IBIS‐CT1 was a prospective longitudinal study enrolling patients with ischemic stroke (IS) or intracerebral hemorrhage (ICH ...
Salomé Retailleau, Marie Bruguet, Irina Viakhireva‐Dovganyuk, François‐Mathias Merrien, Denis Marechal, Aurore Jourdain, Philippe Goas, Jordan Coris, Julien Asselineau, Maëlys Consigny, Gérald Le Gac, Serge Timsit   +11 more
wiley   +1 more source

Clinical Outcomes and New Treatments in Pediatric Brain Tumors. [PDF]

Curr Oncol
Erker C, Perreault S.
europepmc   +1 more source

Baseline Neuroinflammation Stratifies TSPO‐PET Response to Disease‐Modifying Therapy in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch, Markus Matilainen, Giulia N. Baldrighi, Marjo Nylund, Maija Saraste, Laura Airas   +5 more
wiley   +1 more source

Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR/MSI esophagogastric cancers? Results from the IMHOTEP phase II study. [PDF]

ESMO Open
Coutzac C, Zaanan A, de Montfort A, Soularue E, Cohen R, Le Sourd S, Piessen G, Hautefeuille V, Ben Abdelghani M, Blanc E, Svrcek M, Samalin E, Pérol D, de la Fouchardière C.   +13 more
europepmc   +1 more source